Global Non-Small Cell Lung Cancer Therapeutics Market Expanding At A CAGR Of 12.1% From 2015 To 2023, It Is Slated To Achieve A Value Of US$15.1 bn | Bristol-Myers Squibb, Eli Lilly and Company, Boehringer Ingelheim, Pfizer, Inc.

Researchmoz added Most up-to-date research on "Non Small Cell Lung Cancer Therapeutics Market: (By Drug Class: Angiogenesis Inhibitor, EGFR Inhibitor, Kinase Inhibitor, Microtubule Stabilizer, Folate Antimetabolites, and PD-1/PD-L1 Inhibitor): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023" to its huge collection of research reports.

Of late, the demand for non-small cell lung cancer (NSCLC) therapeutics has witnessed a significant surge, globally. The robust rise in the number of patients suffering from NSCLC across the world is likely to strengthen this trend considerably in the near future. The market for NSCLC therapeutics presented a global opportunity worth US$4.9 bn in 2014. Analysts project it to rise at a CAGR of 12.10% during the period from 2015 to 2023 and attain a value of US$15.1 bn by the end of the forecast period.

In this research report, the global NSCLC therapeutics market has been studied with a microscopic view. It aims at presenting a detailed market assessment on the basis of its past as well as current performance. The latest trends and growth opportunities within this market have been examined in-depth to determine its future status in this study.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=497268

Non-Small Cell Lung Cancer Therapeutics Market: Trends and Opportunities

Being the most common type of lung cancer, NSCLC has a large pool of patients suffering from it. Hitherto, angiogenesis inhibitor has been the most successful therapy for NSCLC. The high demand for Avastin in the U.S. and in several European countries is likely to maintain the position of angiogenesis inhibitor as the key treatment for NSCLC in the years to come.

Folate antimetabolites, EGFR inhibitors, and microtubule stabilizers are also expected to gain momentum in the global market over the next few years. In addition, the approval of late-stage pipeline products, such as necitumumab and onartuzumab, are likely to create new revenue streams for drugmakers in the near future.

Non-small Cell Lung Cancer Therapeutics Market: Geographical Analysis

On the basis of geography, the global market for NSCLC therapeutics has been segmented into Europe, Asia Pacific, North America, and the Rest of the World. Thanks to the presence of a state-of-art healthcare infrastructure, North America has emerged as the leading contributor to this market. With favorable insurance and reimbursement scenario, researchers expect this regional market to remain dominant in the forthcoming years.

On the other hand, Asia Pacific is anticipated to offer the most promising opportunities for growth in the near future. The increasing incidence of NSCLC, coupled with unmet medical needs, is likely to make way for the adoption of NSCLC therapeutics at a higher rate. The rise in government initiatives to increase awareness regarding NSCLC among consumers in this region is also projected to propel the Asia Pacific market for NSCLC therapeutics substantially over the next few years.

Companies Mentioned in the Research Report

Owing to the presence of a large pool of players, the global market for non-small cell lung cancer therapeutics demonstrates a highly competitive and fragmented landscape. Genentech Inc., GlaxoSmithKline PLC, Pfizer Inc., Astra Zeneca PLC, Celgene Corp., Eli Lilly & Co., Boehringer Ingelheim, Sun Pharmaceutical Industries Ltd., and Bristol-Myers Squibb are some of the key players in this market across the world.

Key Segments of Non-Small Cell Lung Cancer Therapeutics Market

By Drug Class
- Angiogenesis Inhibitor
- Avastin (bevacizumab)
- Cyramza (Ramucirumab)
- Epidermal Growth Factor Receptor Blocker
- Tarceva (erlotinib)
- Gilotrif (afatinib)
- Iressa (gefitinib)
- Kinase Inhibitor
- Xalkori (crizotinib)
- Zykadia (ceritinib)
- Microtubule Stabilizer
- Abraxane (paclitaxel protein bound)
- Docetaxel
- Folate Antimetabolites
- Alimta (pemetrexed)
- PD-1/ PD-L1 Inhibitor
- Opdivo (nivolumab)
- Keytruda (pembrolizumab)

Get Comple TOC With Tables and Figures @ https://www.researchmoz.us/non-small-cell-lung-cancer-therapeutics-market-global-industry-analysis-size-share-growth-trends-and-forecast-2015-2023-report.html/toc

By Pipeline

- Early Stage (Phase I and II)
- Late Stage (Phase III)
- Avelumab - Pfizer Inc.
- MPDL3280A - Roche
- MEDI4736 - AstraZeneca
- Abemaciclib - Eli Lilly and Company
- Others

Major regions analyzed under this research report are:

- Europe
- North America
- Asia Pacific
- Rest of the World

This report gives you access to decisive data such as:

- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for the coming years

Key highlights of this report

- Overview of key market forces propelling and restraining market growth
- Up-to-date analyses of market trends and technological improvements
- Pin-point analyses of market competition dynamics to offer you a competitive edge
- An analysis of strategies of major competitors
- An array of graphics and SWOT analysis of major industry segments
- Detailed analyses of industry trends
- A well-defined technological growth map with an impact-analysis
- Offers a clear understanding of the competitive landscape and key product segments

Browse Detail Report @ https://www.researchmoz.us/non-small-cell-lung-cancer-therapeutics-market-global-industry-analysis-size-share-growth-trends-and-forecast-2015-2023-report.html

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

ResearchMoz
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Email: sales@researchmoz.us
Website @ https://www.researchmoz.us/
Tel: 866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-621-2074
Follow us on LinkedIn @ http://bit.ly/1TBmnVG

This release was published on openPR.